Magnesium in Coronaries (MAGIC)
Clinical Trials URL:
Study Type: Clinical Trial
Prepared on October 13, 2008
Last Updated on June 23, 2005
Study Dates: 1998-2003
Consent: Unrestricted Consent
Commercial Use Restrictions: No
NHLBI Division: DCVD
Collection Type: Open BioLINCC Study - See bottom of this webpage for request information
To determine whether early intravenous magnesium treatment of patients with suspected acute myocardial infarction reduces mortality.
Mortality rate from ST-elevation myocardial infarction (STEMI) remains high in elderly patients and in patients who are not eligible for reperfusion therapy. Intravenous magnesium is a promising adjunctive treatment that may reduce reperfusion injury. Several earlier trials demonstrated a mortality rate reduction with magnesium treatment, but one large trial found no benefit. If magnesium proves beneficial, its use will provide a simple, cost-effective means to improve survival in this large patient population.
Magnesium in Coronaries (MAGIC) is a large, simple trial designed to maximize the potential treatment effect of magnesium. A total of 6,213 high-risk patients with ST-elevation myocardial infarction were randomly assigned to early treatment with intravenous magnesium sulfate or matching placebo. The primary end point was death at 30 days. Information on the need for treatment of shock and sustained ventricular arrhythmias were collected to investigate the mechanisms by which magnesium might exert a beneficial effect.
Early administration of magnesium in high-risk patients with STEMI had no effect on 30-day mortality. There was no indication for the routine administration of magnesium in patients with STEMI (LANCET 2002; 360: 1189-1196).